The independent platform for news, articles and advice for professionals in laboratory medicine

Procalcitonin assay trial: part of initiative to reduce exposure to antibiotics

The trial of a new procalcitonin assay from Beckman Coulter Diagnostics, undertaken in Portsmouth, is part of an initiative to reduce exposure to antimicrobial agents without a negative impact on patient survival.

More people die each year from sepsis than cancers of the breast and prostate, and HIV/AIDS combined. In the UK alone, it claims 31,000 lives each year, with 1000 cases a year affecting children under five. The financial impact of sepsis is not just the £2 billion it costs the NHS every year, but the devastating effect it can have, often resulting in organ failure and death if undiagnosed or a patient is treated too late.

Procalcitonin (PCT), a prohormone of calcitonin, is an inflammatory marker with a high specificity for bacterial infection. It has been observed as a useful adjunct in determining whether or not a patient has sepsis. A negative procalcitonin result is a point of reassurance to support the cessation of antibiotic treatment, reducing unnecessary associated costs and side-effects. NHS England has made it a requirement for hospitals to use the updated national early warning score (NEWS2) on acute wards, to help identify deteriorating patients.

An initiative by the biochemistry laboratory at Portsmouth’s Queen Alexandra Hospital is designed to explore ways of reducing the impact of such life-threatening infections, while addressing antimicrobial resistance. Its long-term objective is to spearhead new protocols for speeding up appropriate treatment of sepsis with antibiotics within the hospital, placing particular emphasis on patient safety.

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.
Register

Upcoming Events

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

USCAP 113th Annual Meeting

Baltimore Convention Center, Baltimore, Maryland, USA
23-28 March, 2024

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025